CPT code 0566T covers the ultrasound-guided injection of a previously prepared autologous cellular implant, derived from adipose tissue harvested by liposuction, into a single knee. This code represents a minimally invasive biologic procedure aimed at delivering a patient’s own adipose-derived cellular material to the knee joint, relevant in regenerative and orthobiologic care pathways. Nationally, the code matters because it captures a distinct procedure type used in musculoskeletal and regenerative medicine and can affect coverage, coding workflows, and utilization monitoring.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for the procedure, common sites of service, and what the code denotes for billing classification. The publication outlines benchmarks and coverage considerations, highlights typical clinical scenarios where the procedure is applied, and summarizes policy implications for payers and provider billing operations. Data not available in the input for associated taxonomies, specific ICD-10 pairings, and related codes is noted as not provided. The content is intended for a national audience of clinicians, coding professionals, and policy analysts seeking concise information on the clinical and billing identity of CPT code 0566T.